Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.42, $0.40 better than the analyst estimate of $0.02. Revenue for the quarter came in at $32.6 million versus the consensus estimate of $29.21 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.